Nov 5 2026

george

Mobility and VTE

Results of a study linking immobility and VTE: Hoyer EH, Brotman DJ, Young DL, et al. Every step counts: incremental mobility and venous thromboembolism risk among adult general medicine inpatients. J Thromb Haemost. 2026:S1538-7836(26)00566-0. doi: 10.1016/j.jtha.2026.09.006. PMID: 42731731. Available from your local medical library. Abstract Background: Hospital-associated venous thromboembolism (VTE) is a leading but preventable […]

read more

Comments (0)

Thrombophilia

Oct 30 2026

george

October 2026 QQ: Anti-Phospholipid Antibody Summary

Our October 2026 quiz, with 32 respondents, asked, “Which is NOT an antiphospholipid antibody?” The answers reveal participants’ wisdom: Anti beta-2 glycoprotein 1: 1 (3%) Alpha-2 antiplasmin: 23 (72%) Lupus anticoagulant: 1 (3%) Antiprothrombin: 7 (22%) Anticardiolipin: 0 The only mislead that attracted respondents was antiprothrombin, a relatively rare APL that is associated with bleeding. […]

read more

Comments (0)

Quick Question Archive

Oct 28 2026

george

Historical Review Describing Hemorrhage and Thrombosis

Check with your local medical library for Franchini M, Zani M, Focosi D. Human evolution: between hemorrhage and thrombosis. Semin Thromb Hemost. 2026. doi: 10.1055/a-2905-4308. PMID: 42398954. Abstract The human coagulation system has resulted from thousands of years of evolutionary pressure, finely balancing the competing risks of lethal hemorrhage and catastrophic thrombosis. There are several […]

read more

Comments (0)

Bleeding Disorders

Oct 27 2026

george

A Meta-Analysis: Microplastics, Nanoplastics, and Thrombogenesis

Thanks to Dr. Emmanuel Favaloro for featuring this provocative open-access meta-analysis connecting microplastics and hemostasis. Balwan R, Hew YY, Gurumurthy G, et al. Microplastics, nanoplastics, and thrombogenesis. Res Pract Thromb Haemost. 2026;10(7):106931. doi: 10.1016/j.rpth.2026.106931. PMID: 42894845; PMCID: PMC13677222. Abstract Micro- and nanoplastics (MNPs) are produced through mechanical, chemical, and ultraviolet-mediated degradation of plastics and may […]

read more

Comments (0)

Thrombophilia

Oct 20 2026

george

A World Thrombosis Day Post: Blood Clots Can Affect Anyone

Dr. Ali Sadeghi-Khomami: On World Thrombosis Day (13 October), a simple reminder: blood clots can affect anyone, and where a clot forms can have very different consequences. Let’s continue raising awareness about thrombosis, its risk factors, and the importance of early recognition. Know your risk. Recognize the signs. Take action.

read more

Comments (0)

Thrombophilia

Oct 20 2026

george

Reduced-dose DOACs in Cancer-associated Thrombosis

Click for this open-access retrospective cohort study reporting the safety and efficacy outcomes for reduced-dose DOACS: Santini P, Santagata D, Mosoni C, et al. Full- versus reduced-dose direct oral anticoagulants for extended treatment of cancer-associated thrombosis: a multicenter retrospective cohort study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2904-5824. PMID: 42379243. Abstract Extended anticoagulation is recommended in […]

read more

Comments (0)

Anticoagulant Therapy

Oct 12 2026

george

Heparin Effect on Chemiluminescence HIT Testing

Check with your local library for this HIT testing report: Vong R, Pasalic L, Donikian D, Brighton T, Favaloro EJ. Effect of heparin on immunological heparin-induced thrombocytopenia-IgG chemiluminescence testing. Blood Coagul Fibrinolysis. 20261;37(7):329-335. doi: 10.1097/MBC.0000000000001456. PMID: 42615582. Heparin-induced thrombocytopenia (HIT) requires clinical evaluation and laboratory testing using immunological assays with confirmation by functional assays such […]

read more

Comments (0)

Anticoagulant Therapy

Oct 1 2026

george

July 2026 CAP Today Q & A Column: Lipoprotein (a).

Q. Our providers pointed out that lipoprotein(a) results from different laboratories are discordant, so they asked us to bring the assay in-house. Is this a good idea? A. Lipoprotein(a), or Lp(a), is a prothrombotic, proinflammatory, and atherogenic cholesterol-rich particle. Plasma concentration of Lp(a) is an important genetic determinant of atherosclerotic cardiovascular disease (ASCVD) risk, and […]

read more

Comments (0)

Thrombophilia

Sep 30 2026

george

September 2026 QQ Summary: Anticoagulant Therapy for LAC Patients with VTE

Our September 2026 QQ asked: In your facility, what AC do you use for LAC patients with VTE? Our 13 respondents answered: Anti-Xa DOAC: 5 (39%) Warfarin: 8 (61%) No one chose an anti-IIa DOAC, aspirin, or “none.” There have been provocative discussions among KOL experts comparing the long-term use of warfarin (VKA) v. anti-Xa […]

read more

Comments (0)

Thrombophilia

Sep 28 2026

george

Review: Pediatric VTE

While we focus on arterial and venous thrombosis, October 13 is the official World Thrombosis Day. With this thought in mind, here is a richly illustrated review describing pediatric VTE: Espanol MG, Janbain M. Pediatric venous thromboembolism: an illustrated review. Res Pract Thromb Haemost. 2026;10:106892. doi: 10.1016/j.rpth.2026.106892. PMID: 42699084; PMCID: PMC13543900. Abstract Venous thromboembolism (VTE) […]

read more

Comments (0)

Thrombophilia